Cargando…
Evaluation of CD30 expression in B ALL and its correlation with MRD(Minimum Residual Disease)
BACKGROUND: This study was conducted to evaluate CD30 expression in minimum residual disease after chemotherapy in B-acute lymphoblastic leukemia (B-ALL). MATERIALS AND METHODS: This was a cross-sectional study on 30 new cases of B-ALL between 2018 and 2019. We checked CD30 expressions in fresh bone...
Autores principales: | Kazemian, Amirhossein, Nematollahi, Pardis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607176/ https://www.ncbi.nlm.nih.gov/pubmed/34899928 http://dx.doi.org/10.4103/jrms.JRMS_1024_20 |
Ejemplares similares
-
Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year
por: van der Linde, Riana, et al.
Publicado: (2023) -
Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all
por: Kuiper, Roland P., et al.
Publicado: (2021) -
Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)
por: Nagafuji, Koji, et al.
Publicado: (2013) -
NK-cell trogocytosis of CD19 antigen: a rare B-ALL MRD mimicker
por: Panda, Devasis, et al.
Publicado: (2022) -
NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol
por: Svaton, Michael, et al.
Publicado: (2023)